Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study

Antibody engineering has made it possible to design antibodies with optimal characteristics for delivery of radionuclides for tumour imaging and therapy. A humanised divalent-Fab′ cross-linked with a bis-maleimide linker referred to as humanised divalent-Fab′ maleimide was produced as a result of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Casey, J L, Napier, M P, King, D J, Pedley, R B, Chaplin, L C, Weir, N, Skelton, L, Green, A J, Hope-Stone, L D, Yarranton, G T, Begent, R H J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375360/
https://www.ncbi.nlm.nih.gov/pubmed/11986771
http://dx.doi.org/10.1038/sj.bjc.6600198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375360/
https://www.ncbi.nlm.nih.gov/pubmed/11986771
http://dx.doi.org/10.1038/sj.bjc.6600198

Ejemplares similares